{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:11:37Z","timestamp":1793862697901,"version":"4.6.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","award":["Y-SY2021ZD-0110"],"award-info":[{"award-number":["Y-SY2021ZD-0110"]}],"id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","award":["Y-SYBLD2022MS-0142"],"award-info":[{"award-number":["Y-SYBLD2022MS-0142"]}],"id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002402","name":"Sun Yat-Sen University","doi-asserted-by":"publisher","award":["2020009"],"award-info":[{"award-number":["2020009"]}],"id":[{"id":"10.13039\/501100002402","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82230001"],"award-info":[{"award-number":["82230001"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270199"],"award-info":[{"award-number":["82270199"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Science and Technology Program Key Projects","doi-asserted-by":"publisher","award":["2024B03J1291"],"award-info":[{"award-number":["2024B03J1291"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Guangdong Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2024A1515012975"],"award-info":[{"award-number":["2024A1515012975"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012152","name":"National Postdoctoral Program for Innovative Talents","doi-asserted-by":"publisher","award":["BX20240445"],"award-info":[{"award-number":["BX20240445"]}],"id":[{"id":"10.13039\/501100012152","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.medj.2025.100893","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T11:43:25Z","timestamp":1761651805000},"page":"100893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["TQB3617, a bromodomain and extra-terminal inhibitor, in patients with relapsed or refractory lymphoma: A multicenter, phase 1 trial"],"prefix":"10.1016","volume":"7","author":[{"given":"Yuchen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingsong","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baitian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihua","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xunqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiquan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5447-3282","authenticated-orcid":false,"given":"Qingqing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2025.100893_bib1","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.medj.2025.100893_bib2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrd4286","article-title":"Targeting bromodomains: epigenetic readers of lysine acetylation","volume":"13","author":"Filippakopoulos","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.medj.2025.100893_bib3","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.molcel.2014.05.016","article-title":"The mechanisms behind the therapeutic activity of BET bromodomain inhibition","volume":"54","author":"Shi","year":"2014","journal-title":"Mol. Cell"},{"key":"10.1016\/j.medj.2025.100893_bib4","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.medj.2025.100893_bib5","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective inhibition of tumor oncogenes by disruption of super-enhancers","volume":"153","author":"Lov\u00e9n","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.medj.2025.100893_bib6","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1158\/1078-0432.CCR-14-1561","article-title":"The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs","volume":"21","author":"Boi","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2025.100893_bib7","first-page":"E5352","article-title":"Uncovering BRD4 hyperphosphorylation associated with cellular transformation in NUT midline carcinoma","volume":"114","author":"Wang","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.medj.2025.100893_bib8","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1159\/000472407","article-title":"Inhibition of BRD4 Suppresses Cell Proliferation and Induces Apoptosis in Renal Cell Carcinoma","volume":"41","author":"Wu","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.medj.2025.100893_bib9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/cac2.12039","article-title":"BRD2 induces drug resistance through activation of the RasGRP1\/Ras\/ERK signaling pathway in adult T-cell lymphoblastic lymphoma","volume":"40","author":"Tian","year":"2020","journal-title":"Cancer Commun."},{"key":"10.1016\/j.medj.2025.100893_bib10","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ccr.2013.11.003","article-title":"Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma","volume":"24","author":"Chapuy","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.medj.2025.100893_bib11","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1158\/0008-5472.CAN-19-0442","article-title":"BRD4 Promotes Gastric Cancer Progression and Metastasis through Acetylation-Dependent Stabilization of Snail","volume":"79","author":"Qin","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.medj.2025.100893_bib12","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(16)00021-1","article-title":"Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study","volume":"3","author":"Amorim","year":"2016","journal-title":"Lancet. Haematol."},{"key":"10.1016\/j.medj.2025.100893_bib13","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00247-1","article-title":"Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study","volume":"3","author":"Berthon","year":"2016","journal-title":"Lancet. Haematol."},{"key":"10.1016\/j.medj.2025.100893_bib14","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2018.78.2292","article-title":"Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors","volume":"36","author":"Lewin","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2025.100893_bib15","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.annonc.2020.03.294","article-title":"Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed\/refractory non-Hodgkin's lymphoma","volume":"31","author":"Moreno","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.medj.2025.100893_bib16","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/s41467-023-36976-1","article-title":"BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas","volume":"14","author":"Moreno","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.medj.2025.100893_bib17","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1158\/2767-9764.CRC-22-0060","article-title":"A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma","volume":"2","author":"Blum","year":"2022","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.medj.2025.100893_bib18","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1158\/1078-0432.CCR-22-1284","article-title":"A Phase I\/II Open-Label Study of Molibresib for the Treatment of Relapsed\/Refractory Hematologic Malignancies","volume":"29","author":"Dawson","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2025.100893_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkz093","article-title":"Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors","volume":"4","author":"Piha-Paul","year":"2020","journal-title":"JNCI Cancer Spectr."},{"key":"10.1016\/j.medj.2025.100893_bib20","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41416-020-01180-1","article-title":"A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma","volume":"124","author":"Shapiro","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.medj.2025.100893_bib21","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.celrep.2014.08.025","article-title":"Inducible in vivo silencing of Brd4 identifies potential toxicities of sustained BET protein inhibition","volume":"8","author":"Bolden","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.medj.2025.100893_bib22","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41586-020-1930-8","article-title":"Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer","volume":"578","author":"Faivre","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.medj.2025.100893_bib23","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1182\/blood-2016-08-692566","article-title":"Peripheral T-cell lymphoma, not otherwise specified","volume":"129","author":"Broccoli","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.medj.2025.100893_bib24","first-page":"859","article-title":"The discovery and development of romidepsin for the treatment of T-cell lymphoma","volume":"12","author":"Smolewski","year":"2017","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.medj.2025.100893_bib25","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2025.100893_bib26","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2025.100893_bib27","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2025.100893_bib28","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.medj.2025.100893_bib29","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2021-148939","article-title":"Duvelisib in Patients with Relapsed\/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Results of an Interim Analysis","volume":"138","author":"Brammer","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.medj.2025.100893_bib30","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-\u03b4,\u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.medj.2025.100893_bib31","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1158\/1078-0432.CCR-24-1194","article-title":"A Phase Ib Study of Linperlisib in the Treatment of Patients with Relapsed and\/or Refractory Peripheral T-cell Lymphoma","volume":"30","author":"Jin","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2025.100893_bib32","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-025-01697-z","article-title":"A multicenter, open-label, single-arm, phase Ib clinical trial of HH2853 treatment in patients with relapsed and\/or refractory peripheral T-cell lymphoma","volume":"18","author":"Hong","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.medj.2025.100893_bib33","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/1078-0432.CCR-23-2582","article-title":"Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study","volume":"30","author":"Song","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2025.100893_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28073043","article-title":"BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications","volume":"28","author":"To","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.medj.2025.100893_bib35","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1158\/1078-0432.CCR-23-1429","article-title":"Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed\/Refractory Myeloid Malignancies","volume":"29","author":"Senapati","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2025.100893_bib36","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1158\/1078-0432.CCR-23-0133","article-title":"A Phase I\/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive\/HER2-negative Advanced or Metastatic Breast Cancer","volume":"30","author":"Cescon","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2025.100893_bib37","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ccell.2018.03.024","article-title":"Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms","volume":"33","author":"Kleppe","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.medj.2025.100893_bib38","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1200\/JCO.22.01972","article-title":"MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Na\u00efve Myelofibrosis","volume":"41","author":"Mascarenhas","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2025.100893_bib39","doi-asserted-by":"crossref","first-page":"6502","DOI":"10.1200\/JCO.2024.42.16_suppl.6502","article-title":"Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-na\u00efve patients with myelofibrosis","volume":"42","author":"Rampal","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2025.100893_bib40","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634025003204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634025003204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T16:17:17Z","timestamp":1767975437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634025003204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2666634025003204"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2025.100893","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TQB3617, a bromodomain and extra-terminal inhibitor, in patients with relapsed or refractory lymphoma: A multicenter, phase 1 trial","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2025.100893","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100893"}}